51
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Attrition during the period from HIV testing to antiretroviral therapy (ART) initiation is high worldwide. We assessed whether same-day HIV testing and ART initiation improves retention and virologic suppression.

          Methods and findings

          We conducted an unblinded, randomized trial of standard ART initiation versus same-day HIV testing and ART initiation among eligible adults ≥18 years old with World Health Organization Stage 1 or 2 disease and CD4 count ≤500 cells/mm 3. The study was conducted among outpatients at the Haitian Group for the Study of Kaposi’s Sarcoma and Opportunistic infections (GHESKIO) Clinic in Port-au-Prince, Haiti. Participants were randomly assigned (1:1) to standard ART initiation or same-day HIV testing and ART initiation. The standard group initiated ART 3 weeks after HIV testing, and the same-day group initiated ART on the day of testing. The primary study endpoint was retention in care 12 months after HIV testing with HIV-1 RNA <50 copies/ml. We assessed the impact of treatment arm with a modified intention-to-treat analysis, using multivariable logistic regression controlling for potential confounders. Between August 2013 and October 2015, 762 participants were enrolled; 59 participants transferred to other clinics during the study period, and were excluded as per protocol, leaving 356 in the standard and 347 in the same-day ART groups. In the standard ART group, 156 (44%) participants were retained in care with 12-month HIV-1 RNA <50 copies, and 184 (52%) had <1,000 copies/ml; 20 participants (6%) died. In the same-day ART group, 184 (53%) participants were retained with HIV-1 RNA <50 copies/ml, and 212 (61%) had <1,000 copies/ml; 10 (3%) participants died. The unadjusted risk ratio (RR) of being retained at 12 months with HIV-1 RNA <50 copies/ml was 1.21 (95% CI: 1.04, 1.38; p = 0.015) for the same-day ART group compared to the standard ART group, and the unadjusted RR for being retained with HIV-1 RNA <1,000 copies was 1.18 (95% CI: 1.04, 1.31; p = 0.012). The main limitation of this study is that it was conducted at a single urban clinic, and the generalizability to other settings is uncertain.

          Conclusions

          Same-day HIV testing and ART initiation is feasible and beneficial in this setting, as it improves retention in care with virologic suppression among patients with early clinical HIV disease.

          Trial registration

          This study is registered with ClinicalTrials.gov number NCT01900080

          Abstract

          In a randomized unblinded trial in Port-au-Prince, Haiti, Serena Koenig and colleagues investigate whether initiating ART on the day of HIV diagnosis improved retention in care and viral suppression.

          Author summary

          Why was this study done?
          • Multiple visits for counseling, laboratory testing, and other procedures to prepare patients for initiation of antiretroviral therapy (ART) are burdensome and contribute to the high rate of attrition during the period from HIV testing to ART initiation.

          • The World Health Organization (WHO) recently changed their guidelines to recommend ART for all persons living with HIV, facilitating ART initiation.

          • This study was conducted to determine if ART initiation on the day of HIV diagnosis could improve treatment initiation rates, retention in care, and HIV viral suppression for patients with asymptomatic or minimally symptomatic HIV disease.

          What did the researchers do and find?
          • We randomly assigned patients who presented for HIV testing at a clinic in Port-au-Prince, Haiti to standard ART initiation or same-day HIV testing and ART initiation (356 in the standard and 347 in the same-day groups).

          • The standard group had 3 weekly visits with a social worker and physician and then started ART 21 days after the date of HIV diagnosis; the same-day ART group initiated ART on the day of HIV diagnosis.

          • All participants in the same-day ART group and 92% of participants in the standard group initiated ART.

          • At 12 months after HIV testing, a higher proportion of participants in the same-day ART group were retained in care (80% versus 72%), and a higher proportion were retained in care with viral load <50 copies/ml (53% versus 44%) and viral load <1,000 copies/ml (61% versus 52%).

          What do these findings mean?
          • This study demonstrates that it is feasible to initiate ART on the day of HIV diagnosis for patients with early HIV clinical disease and that same-day treatment leads to increased ART uptake, retention in care, and viral suppression.

          • Though same-day ART initiation improves outcomes, retention in care and viral suppression remain suboptimal, so further interventions to maximize long-term outcomes will be essential.

          • The study is limited by being conducted at 1 clinic in urban Haiti. Further study will be necessary to determine if this strategy will be effective in other settings.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: found
          • Article: not found

          Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial

          Summary Background Robust evidence of the effectiveness of task shifting of antiretroviral therapy (ART) from doctors to other health workers is scarce. We aimed to assess the effects on mortality, viral suppression, and other health outcomes and quality indicators of the Streamlining Tasks and Roles to Expand Treatment and Care for HIV (STRETCH) programme, which provides educational outreach training of nurses to initiate and represcribe ART, and to decentralise care. Methods We undertook a pragmatic, parallel, cluster-randomised trial in South Africa between Jan 28, 2008, and June 30, 2010. We randomly assigned 31 primary-care ART clinics to implement the STRETCH programme (intervention group) or to continue with standard care (control group). The ratio of randomisation depended on how many clinics were in each of nine strata. Two cohorts were enrolled: eligible patients in cohort 1 were adults (aged ≥16 years) with CD4 counts of 350 cells per μL or less who were not receiving ART; those in cohort 2 were adults who had already received ART for at least 6 months and were being treated at enrolment. The primary outcome in cohort 1 was time to death (superiority analysis). The primary outcome in cohort 2 was the proportion with undetectable viral loads (<400 copies per mL) 12 months after enrolment (equivalence analysis, prespecified difference <6%). Patients and clinicians could not be masked to group assignment. The interim analysis was blind, but data analysts were not masked after the database was locked for final analysis. Analyses were done by intention to treat. This trial is registered, number ISRCTN46836853. Findings 5390 patients in cohort 1 and 3029 in cohort 2 were in the intervention group, and 3862 in cohort 1 and 3202 in cohort 2 were in the control group. Median follow-up was 16·3 months (IQR 12·2–18·0) in cohort 1 and 18·0 months (18·0–18·0) in cohort 2. In cohort 1, 997 (20%) of 4943 patients analysed in the intervention group and 747 (19%) of 3862 in the control group with known vital status at the end of the trial had died. Time to death did not differ (hazard ratio [HR] 0·94, 95% CI 0·76–1·15). In a preplanned subgroup analysis of patients with baseline CD4 counts of 201–350 cells per μL, mortality was slightly lower in the intervention group than in the control group (0·73, 0·54–1.00; p=0·052), but it did not differ between groups in patients with baseline CD4 of 200 cells per μL or less (0·94, 0·76–1·15; p=0·577). In cohort 2, viral load suppression 12 months after enrolment was equivalent in intervention (2156 [71%] of 3029 patients) and control groups (2230 [70%] of 3202; risk difference 1·1%, 95% CI −2·4 to 4·6). Interpretation Expansion of primary-care nurses' roles to include ART initiation and represcription can be done safely, and improve health outcomes and quality of care, but might not reduce time to ART or mortality. Funding UK Medical Research Council, Development Cooperation Ireland, and Canadian International Development Agency.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study.

            Loss to follow-up of HIV-positive patients before initiation of antiretroviral therapy can exceed 50% in low-income settings and is a challenge to the scale-up of treatment. We implemented point-of-care counting of CD4 cells in Mozambique and assessed the effect on loss to follow-up before immunological staging and treatment initiation. In this observational cohort study, data for enrolment into HIV management and initiation of antiretroviral therapy were extracted retrospectively from patients' records at four primary health clinics providing HIV treatment and point-of-care CD4 services. Loss to follow-up and the duration of each preparatory step before treatment initiation were measured and compared with baseline data from before the introduction of point-of-care CD4 testing. After the introduction of point-of-care CD4 the proportion of patients lost to follow-up before completion of CD4 staging dropped from 57% (278 of 492) to 21% (92 of 437) (adjusted odds ratio [OR] 0·2, 95% CI 0·15-0·27). Total loss to follow-up before initiation of antiretroviral treatment fell from 64% (314 of 492) to 33% (142 of 437) (OR 0·27, 95% CI 0·21-0·36) and the proportion of enrolled patients initiating antiretroviral therapy increased from 12% (57 of 492) to 22% (94 of 437) (OR 2·05, 95% CI 1·42-2·96). The median time from enrolment to antiretroviral therapy initiation reduced from 48 days to 20 days (p<0·0001), primarily because of a reduction in the median time taken to complete CD4 staging, which decreased from 32 days to 3 days (p<0·0001). Loss to follow-up between staging and antiretroviral therapy initiation did not change significantly (OR 0·84, 95% CI 0·49-1·45). Point-of-care CD4 testing enabled clinics to stage patients rapidly on-site after enrolment, which reduced opportunities for pretreatment loss to follow-up. As a result, more patients were identified as eligible for and initiated antiretroviral treatment. Point-of-care testing might therefore be an effective intervention to reduce pretreatment loss to follow-up. Absolute Return for Kids and UNITAID. Copyright © 2011 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Toward an Understanding of Disengagement from HIV Treatment and Care in Sub-Saharan Africa: A Qualitative Study

              Introduction The rollout of antiretroviral therapy (ART) in sub-Saharan Africa has brought lifesaving treatment to millions of HIV-infected individuals. To continue to benefit from therapy, however, patients must remain in care. Ensuring long-term retention in care and treatment for HIV/AIDS has proven challenging in resource-scarce settings [1]–[5]. Tracking studies in which patients lost to follow-up are sought in the community to ascertain outcomes suggest that 20%–80% of patients “lost” but alive are no longer in care [6],[7]. Previous research by Geng et al. [8] using tracking data to estimate outcomes for a large clinic population indicated that approximately one in six patients taking ART were not in care after 2 y. Understanding disengagement from care is essential to improving retention and, thus, long-term outcomes of treatment. The existing literature on barriers to ART adherence sheds considerable light on the retention problem. Since adherence means not only following dosing regimens but also being able to refill prescriptions, and since prescriptions are refilled as part of routine follow-up visits in Africa, barriers to adherence and retention overlap. Travel distance to clinic sites and associated costs, stigma and fear of disclosure, competing demands for scarce resources, religious and cultural beliefs, and unanticipated obligations and events (e.g., attending a family funeral) are key adherence barriers identified through previous research that also bear upon retention [9]–[14]. Motivation stemming from improved health following ART initiation, material and emotional support from others, and the promise of increased longevity are overlapping facilitators [15],[16]. As retention research develops, a number of patterns are emerging to suggest factors shaping disengagement. Disengagement rates appear particularly high for patients who have not yet initiated ART [17]–[23], and lower in decentralized care sites [24]–[27]. There is some evidence that younger patients, men, pregnant women, and individuals who have not disclosed their HIV status disappear from care more frequently [23],[28]–[32]. A wide variety of contributors to missed visits have been cited in patients' own accounts. Patient-reported barriers include travel distance to clinic, and associated time and expense; traveling/being away from home on the visit date; fear of disclosure; stigma; dissatisfaction with care; improved health; discouragement and the desire to “give up”; “return to normal life”; and a relatively low perception of risk associated with HIV [33]–[40]. Psychological facilitators have also been suggested, among them motivation, high perceived risk associated with HIV, and a sense of self-efficacy (feeling capable of meeting treatment requirements) [35],[41]. The number of studies with data on reasons for missed visits collected from patients has grown rapidly in recent years. In most cases, these data are reported simply as lists of reasons patient participants have provided, stopping short of deeper analysis. For a more integrated, interpretive approach, we may look to the “meta-ethnography” by Merten et al. [40], which reviewed existing qualitative studies and integrated data to propose an explanatory “line of argument”. Drawing inductively upon results from 31 primary studies, the authors highlighted the importance of social processes in mediating ART adherence and retention in HIV care in Africa. Patients' “social integrity” and “social careers”—both of which refer to negotiation of social relationships in the context of ART treatment—were offered as concepts to clarify the social processes involved. The goals of our research are also explanatory. Our conceptual starting point is a social contextual explanation of ART adherence in Africa centering on patients' sense of social responsibility as a motivating factor. This sense of responsibility is seen as a reciprocal response to material and emotional help from family, treatment supporters, health care providers, and others without which continued adherence to ART and to clinic follow-up appointments would not be possible. As recipients of ongoing adherence help, individuals taking ART feel a responsibility to helpers to succeed at therapy. Success thus becomes both a social responsibility and a means of ensuring help continues to be available into the future [42]. This qualitative, patient-centered research aimed to help explain missed clinic visits and subsequent disengagement from HIV/AIDS treatment and care in sub-Saharan Africa. The study took place in three African countries—Nigeria, Tanzania, and Uganda—and had two objectives. First, we set out to inductively identify and characterize in depth reasons for missed visits from the perspectives of patients. Second, we worked to assemble identified reasons into a broader explanation of missed visits and disengagement from care. Methods Country Settings and Clinical Study Sites Tanzania, Uganda, and Nigeria represent diverse geographic and cultural settings. However, all three countries have generalized HIV epidemics in which women are disproportionately affected [43]. Characteristics of the epidemics vary across countries, but all three have seen prevalence rates drop with global scale-up of free ART. Huge health gains have resulted from the scale-up effort, yet more than half of eligible adults remain without access to therapy. Recent estimates place the number of adults living with HIV/AIDS at 1–1.5 million in Tanzania and Uganda, and at 3.3 million in Nigeria (see Table 1). The difference in numbers reflects population differences, at least in part. At approximately 160 million, Nigeria's population is the largest of all African countries. The number of adults living with HIV/AIDS in Nigeria is reported to be the third highest in the world [44]. 10.1371/journal.pmed.1001369.t001 Table 1 Characteristics of country settings [63]–[74]. Characteristic Country Nigeria Uganda Tanzania Population 158,423,000 (2010) 33,425,000 (2010) 44,841,000 (2010) HIV prevalence before ART scale-up 4.5% (1998) 8.3% (1999) 8.0% (1998) Year free ART became available 2006 2004 2004 HIV prevalence after ART scale-up 3.6% [3.3%–4%] (2009) 6.5% [5.9%–6.9%] (2009) 5.6% [5.3%–6.1%] (2009) Number of adults on ART 359,200 (2010) 248,200 (2010) 258,100 (2010) Percent eligible receiving ART 31.0% (2009) 47.0% (2011) 50.0% (2010) Number of adults living with HIV 3.3 million [2.9–3.6 million] (2009) 1.2 million [1.1–1.3 million] (2009) 1.4 million [1.3–1.5 million] (2009) 95% CIs given in brackets; year given in parentheses. Participating clinical study sites were the Jos University Teaching Hospital (JUTH) AIDS Prevention Initiative in Nigeria HIV/AIDS Clinic (APIN Clinic) in Jos, Nigeria; the Mwananyamala Hospital HIV/AIDS Care and Treatment Center in Dar es Salaam, Tanzania; and the Mbarara Regional Referral Hospital Immune Suppression Syndrome Clinic (ISS Clinic) in Mbarara, Uganda. All three are large clinics providing comprehensive treatment, care, and support services for patients with HIV/AIDS. Physicians, nurses, counselors, and pharmacists provide services to patients, supported by technical, administrative, and ancillary staff. The total number of direct care staff ranges widely across the sites, from fewer than 30 to more than 70 (full- and part-time). The JUTH APIN Clinic serves the city of Jos, with a population of approximately 1.5 million, and the surrounding central plateau region of Nigeria. Mwananyamala Hospital HIV/AIDS Care and Treatment Center serves the Kinondoni Municipality of Dar es Salaam, Tanzania's largest city, numbering about 4 million people. The ISS Clinic serves the Mbarara District of southwest Uganda and parts of neighboring districts (approximately 3 million people). Additional information about participating clinical study sites appears in Table 2. 10.1371/journal.pmed.1001369.t002 Table 2 Characteristics of participating study sites. Characteristic APIN Clinic (Jos, Nigeria) Mwananyamala Hospital HIV/AIDS Care and Treatment Center (Dar es Salaam, Tanzania) ISS Clinic (Mbarara, Uganda) Geographic setting Urban Urban Peri-urban and rural Size of population served 22 million 4 million 3 million Year opened 2002 2004 1998 Total adults enrolled in HIV/AIDS care 17,139 16,107 21,149 Total adults currently followed 10,532 5,478 8,808 Adults currently followed on ART 8,854 3,930 7,140 Patient Tracking for Research and Clinical Care With the identification of loss to follow-up as a threat to the long-term success of ART scale-up in Africa, patient tracking has been increasingly relied upon by researchers as a means of obtaining information on patients who have missed clinic visits [7],[8],[37],[38]. At the same time, local treatment program planners and health care practitioners have independently developed patient tracking as part of HIV clinical care. For clinical purposes, tracking is used to encourage retention and to contact patients who need to be seen outside of regular appointment schedules. Clinical trackers are trained health care workers or volunteers. Permission for tracking is requested from patients at enrollment in care. In-person patient tracking is a culturally meaningful clinical strategy for making contact with patients in the absence of highly developed telecommunications systems. As mobile phones become more widely available, telephone tracking is replacing the in-person approach. Clinical trackers travel outside clinics to locate patients in the community. From lists of patients to be tracked, trackers organize itineraries for in-person tracking and lists of individuals to be followed up by telephone, then attempt to make contact. The tracking programs at the three clinical sites participating in this study differed in size, mode of transport, reliance on phone versus in-person tracking, and distance traveled to locate patients. Differences reflected distinctions in clinic policy and/or local practice. Trackers at all three sites were paid and received training in HIV treatment, ethical practice, and tracking procedures. Sampling and Recruitment The sample for this study was generated using clinic tracking lists. The lists identified adult patients aged 18 y and older who were (1) enrolled in care, (2) had missed a regularly scheduled follow-up visit, and (3) had not subsequently returned to the clinic for 3 mo or more. A 3-mo period of absence was chosen following the practices of participating clinics for identifying patients to be tracked. Lists of persons fulfilling these criteria were generated by data managers at the sites from clinic databases and forwarded to clinic trackers for follow-up. When an individual was contacted through clinic tracking, and after standard clinic tracking procedures had been completed, trackers briefly introduced the research using an institutional-review-board-approved script, and requested permission for follow-up by study research assistants. Individuals giving permission were then recontacted by research assistants, who described the study in detail, answered questions, and enrolled those who expressed interest in participating. Thus, individuals participating in the study met the following inclusion criteria: (1) were absent from the clinic for 3 mo or more, (2) were tracked and contacted by clinic trackers, (3) gave permission for additional follow-up by study research assistants, (4) were successfully recontacted by study research assistants, and (5) were able and willing to provide informed consent. Ethics This study was approved by the Harvard Medical School Committee on Human Studies, Boston, Massachusetts; the JUTH Institutional Health Ethical Research Committee, Jos, Nigeria; the Muhimbili University of Health and Allied Sciences Senate Research and Publications Committee, Dar es Salaam, Tanzania; the Mbarara University of Science and Technology Institutional Review Committee, Mbarara, Uganda; and the Uganda National Council on Science and Technology, Kampala, Uganda. All study participants provided written informed consent. Compensation in the form of cash and/or reimbursement for travel to interview locations was provided. Amounts and forms of compensation were determined in consultation with investigators and ethical review boards at participating sites. Data Collection Data were collected from 15 January 2010 through 30 March 2012 using in-depth in-person interviews with enrolled patient participants. Consistent with an inductive approach, interviews were designed to be flexible, following a general, topic-oriented structure. Topics were selected to address the goals of the research and included the following: (1) experiences of care at the clinic, (2) experiences of tracking, and (3) circumstances of missed appointments. Interviews sought to elicit detailed accounts of actual experiences of interviewees from their points of view. They were conducted by trained research assistants in each of the three countries in local languages, and were audio-recorded with permission. They took place in private locations—at patients' homes or at other convenient places of their choosing—and lasted approximately one hour. Data Preparation Upon completion of each interview, interviewers produced a complete transcript in English from local language audio-recordings. Each transcript was reviewed for quality by M. A. W. Interviewers made additions and corrections to transcripts as indicated by the quality review. The transcripts constituted the study data. Data Analysis Analysis of data aimed to characterize patients' reasons for missing clinic visits and to represent them as descriptive categories. An inductive approach to concept development centering on category construction and informed by grounded theory methodology [45],[46] was used to carry out the analysis. Analysis began with repeated review of interview transcripts to identify sections of text illuminating reasons for missing clinic visits. These sections of text were displayed in matrices to reduce the data and facilitate identification of content similarities or patterns. Sections of text determined to be similar in content were grouped and assigned provisional labels to form an initial set of “reason categories.” The initial category set was then reviewed to confirm that labels accurately reflected corresponding sections of text. Labels were revised as necessary to strengthen correspondences and improve precision. Illustrative quotes were retrieved from interview transcripts. Multiple authors participated in this process. Disagreements and inconsistencies arising in the analytic process were resolved through discussion. Data from the three sites were analyzed separately. Once the categories were formulated, they were examined interpretively for broader underlying dimensions and relationships to each other. This interpretive analysis allowed us to move beyond a listing of individual reasons for missing clinic appointments toward a larger, more integrated explanation, and to highlight previously underemphasized aspects of the problem. Categories were then further grouped to represent “unintentional” versus “intentional” reasons for missing appointments and were loosely arranged in time sequence. Of course, other interpretations are possible. Our goal was to advance thinking and research on disengagement from HIV care in sub-Saharan Africa by proposing new conceptualizations suggested by qualitative data. Results Outcomes of Tracking Eight-hundred-ninety patients were tracked at the three sites as part of recruitment. Two-hundred-eighty-seven were located, and 91 ultimately took part in the study (see Table 3). Of the 91 participants, 76 were being prescribed ART; 15 had not initiated treatment. Length of time out of care varied widely across the sample of participants. Reasons for not participating in the study among located patients included the following: (1) refusal to give permission for follow-up contact for research, (2) denial of HIV-positive status to trackers, (3) fear of disclosure of HIV status as a result of research participation, and (4) preference for remaining uninvolved in any further HIV-focused activity (treatment or research). Of 603 patients tracked but not located, 211 (35%) were reported dead, 144 (24%) had moved, and 79 (13%) were traveling away from home at the time of tracking visits. No information could be obtained for the remainder. 10.1371/journal.pmed.1001369.t003 Table 3 Study tracking activities and outcomes. Site Number of Trackers Participating Tracking Period for Study Recruitment Number of Patients Tracked Number of Patients Located (Percent) Number of Patients Enrolled Jos, Nigeria 3 18 mo 254 140 (55%) 40 Dar es Salaam, Tanzania 19 6 mo 208 46 (22%) 20 Mbarara, Uganda 2 17 mo 428 101 (24%) 31 Of the 140 people located in Jos, 17 (12%) were tracked by home visit only (no phone). In Mbarara and Dar es Salaam, the large majority of people were tracked by home visit only. Characteristics of Interviewees The average age of patient interviewees was 36 years. Almost 60% were women; 62% were Christian. On average, they had a little less than 10 y of education. Three-quarters of interviewees reported being employed. Median reported travel time to clinic was about 45 min. Nigerian participants had more years of schooling than Ugandan or Tanzanian participants, and were more likely to be employed than Tanzanian participants. Travel time to clinic was longest in Uganda. Characteristics of patient interviewees are detailed in Table 4. 10.1371/journal.pmed.1001369.t004 Table 4 Patient participant interviewee characteristics. Characteristic All (n = 91) Nigeria (n = 40) Tanzania (n = 20) Uganda (n = 31) Gender female (percent) 59.3 62.5 55.0 58.1 Age (years), mean (SD) 35.9 (8.1) 34.9 (7.4) 39.3 (9.0) 35.0 (8.1) Religion (percent) Christian 61.5 52.5 50.0 80.1 Muslim 38.5 47.5 50.0 19.4 Education (years), mean (SD) 9.8 (3.9) 11.9 (3.7) 9.1 (2.8) 7.6 (3.6) Employment (percent) Employed 75.8 85.0 55.0 77.4 Unemployed 24.2 15.0 45.0 22.6 Travel time to clinic (minutes), median (IQR) 45 (30–120) 30 (30–60) 30 (30–52.5) 120 (60–180) IQR, interquartile range; SD, standard deviation. Reasons for Missing Visits Core terms used in the discourse on retention in HIV treatment and care reflect the evolution of research and thinking on the topic, while pointing to one or another potential source of retention problems. “Loss to follow-up” connotes clinics' difficulties in keeping track of patients, while patient-centered terms—the currently preferred “disengagement” or the African term “defaulter”—imply that missed visits result from patient choice. In contrast, it was the unintentional origins of missed visits that stood out among our study participants. Interviewees continually confronted competing demands on their time. When demands stemmed from cultural and family obligations, or economic requirements—e.g., caring for a sick family member in a distant location, traveling for work, attending a relative's funeral in another town—they took precedence over keeping clinic appointments. The following interview excerpt illustrates this: I went to the village in December and when it was time to come back before my appointment of January 3, 2011, I was not able to come back because I lost a brother. A few days after losing my brother, I lost another relative and so I stayed in the village. I had planned to come back on January 1, since my clinic appointment was for January 3, but I did not come back. [Female, age 27] Plans were routinely upended by unexpected events, another source of unintentional absences. Accidents, vehicle breakdowns, and other travel delays meant that individuals who had traveled but planned to return before their clinic visit date were stranded away from home, as in the following case: What caused me not to come to the clinic was that I lost my father. When he died, I went to [name of town] for the burial and the money that I had taken with me ran out. And so I had to first stay there to make some more to facilitate my return. When I was able to return to my home, I failed to get the money for transport to the hospital and so I started working to be able to earn the amount enough to facilitate my transport fare. [Male, age 40] Encounters with violence were obstacles for some patients. Lack of support from family and community in the form of failure to provide transport funds or of active opposition to care led to unintentional absences for some interviewees. Errors—misunderstanding visit dates or forgetting an appointment—were another unintentional reason for missing. Some missed visits were intentional. For example, patients might decide to stop attending a particular clinic as decentralization initiatives provided the option of receiving care closer to home. Patients offered an alternative to long, expensive travel for care transferred to local facilities. If transfers were not recorded at the initial care sites, those patients were categorized as “missing.” When patients decided to stop keeping clinic appointments, the reason could also be dissatisfaction with care. Interviewees reported objections to clinic policy (e.g., insistence on adherence to certain days and times of appointments) or some aspect of care organization (e.g., clinic schedules that made for long waiting times). Interviewees also complained of harsh treatment by providers. Harsh treatment typically referred to behavior perceived by patients to be rude and/or rejecting. For example, interviewees reported being spoken to “roughly” or feeling that the clinic staff “didn't care.” “Shouting” and “bad language” were cited. At one site, references were made to threats that missed visits would result in being dropped from care. Experiences of harsh treatment left patients feeling hurt, angry, and humiliated, as the following quotes illustrate: I felt humiliated. I felt very bad. After receiving the services I was full of pain. After that incident I didn't go back to the hospital. I decided to leave everything and opt for fruits and food…and until now I am not taking it [ART]. [Male, age 60] Like my last clinic visit, it became too much. They really looked like they didn't care. [Interviewer: Why do you say they looked like they didn't care?] When people come to the clinic and go to their [consulting] rooms, they don't care about them. There are many patient files piled on their desks but they just sit there. Or sometimes, they come, look at the files and then just go their own way. Or sometimes when you enter the doctor's room, they start conversing and talking about their own things while you just sit there and wait for them to finish. [Female, age 27] …the first day I came, I didn't know I had to drop my card—hand card—by the door. So I came in and sat down where my friend said. The nurse there was so harsh that I didn't drop my card. She said all nasty things to me and at a point I said, “Amen! Let me just go.” That was the first day; that was the first experience. I felt it was not a place to be. It was like I should just leave the hospital immediately. [Female, age 35] They [staff] told me, “You are late.” Now, there are problems people face. I don't know how they perceive it but for me this thing is very difficult. Attending clinic every month is very difficult, because you have to leave your work, sometimes report [to work] late—reasons like these. Everyone has problems. They are supposed to solve these problems with love, not harshly like they do. Until people are afraid of their words—abusive words. They behave as if we are there to beg for meds. It's our right to get the meds. [Female, age 34] Examined closely, absences are revealed to be less the simple result of one or another “reason” taken individually, and more the product of complex chains of events. To identify only the initial, “surface” reason is to provide an incomplete, sometimes inaccurate, account. For a full understanding, one must follow the events in the chain. An example is the frequently cited “problem of transport.” Transport problems often gloss a much more complicated set of circumstances. In the following instance, for example, an interviewee who began his explanation of missed visits by citing a “transport problem,” went on to reveal more about what that problem led to and meant: We fail to get vehicles sometimes. And when you go to look for money for [a motorcycle taxi] you find you do not have it. So when you miss your appointment and go to clinic on another day, [the provider] starts quarreling with you about not having come on the appointed day. And when you tell that person you got problems, he tells you, “You should spend the night on the road.” How can I spend the night on the road? Here I am, having failed to get money for taking me to the hospital and then I'm supposed to get money to spend the night somewhere and feed myself? These are some of the problems I have in going to the clinic. [Male, age 56] This patient became discouraged and abandoned care—not so much due to transport difficulties as to the lack of understanding and accommodation of these difficulties by staff. When located for this study, he had not been seen for care for 2 y. In addition to being complex, many obstacles to missed visits are also transitory. They end, dissipate, or cease to be obstacles as circumstances change over time. Recognizing this raises the question, if initial obstacles no longer block clinic attendance, why don't patients who miss visits then return? A strong reluctance to return for care after an absence emerged from the qualitative data. I was scared to come back to the clinic since a lot of time had already passed and I might come back and they chase me away. [Male, age 40] I was scared of coming back and them telling me that they will not accept me because I didn't come when they told me to. I was wondering whether they would accept me or not or whether they would scold me. [Female, age 35] I was afraid to go back because I didn't have my card and I stopped meds for a long time. I was afraid the nurses would yell at me. [Female, age 35] Reluctance to Return Two reasons for this reluctance stand out. The first centers on a sense of shame articulated by interviewees, who felt a strong sense of the responsibility that comes with starting ART. Having gained access to a valuable resource in a resource-scarce environment, and having been extensively “educated” as to the adherence commitment access to that resource entails, patients who miss clinic visits seemed to see themselves as having failed to live up to their responsibilities when they missed visits and experienced a treatment lapse. The following quotes illustrate this: When they accept us and open our files, they tell us this—that when you start, you should not stop. And if you know you will play with it, then do not start. So it was because I know I was wrong. That is why I said I will not be able to return. [Female, age 25] In fact, when [the tracker] called me, I felt a sense of guilt. This is my health. I am supposed to be worrying about my health, not somebody else worrying about my health—you know? [Male, age 46] Apprehension at anticipated negative responses from care providers is a second explanation suggested by the data for reluctance to return. Over time, the distress at perceived poor treatment prompting patients to miss visits evolves into anticipation of the painful encounters they see awaiting them upon return. Interviewees articulated a fear of being “yelled at,” “abused,” and/or “chased” from the clinic should they attempt to resume treatment after an absence. Rather than face this, they simply stayed away. I was afraid to go back because I had stopped meds for a long time and I didn't have my [clinic identity] card. I was afraid the nurses would yell at me…. [Female, age 35] I did not come back on the date I was given. When the date for me to go back to the clinic had passed, I feared I would be abused if I went back past my appointment date. [Female, age 20] I was scared to come back to the clinic since a lot of time had already passed and I might come back and they chase me away. [Female, age 20] The way she told me, “Why did you miss clinic…despite what happened, you should have come to the clinic and met other people.” I told her no, I didn't want to show up because what happened to me [at the clinic] was still in my heart. If I was treated nicely the situation would have been different; since I was treated badly I saw the treatment was meaningless. [Male, age 60] [Interviewer: The situation of stopping care or treatment at the clinic, how did that make you feel?] It made me feel bad to see that I had to go to get meds. Looking at how badly the provider spoke to me, I asked him how they would be benefiting from my death? I said to myself, “Let me leave these things. If I am to die let me do that—die.” [Male, age 56] Reluctance to return, whether originating in shame at having failed to fulfill a responsibility or apprehension about the anticipated negative response of providers, signals the erosion of a subjective sense of connectedness to the idea, processes, and, for some, the specific site of care. We propose it is this sense of connectedness, together with family and community support, that fuels patients' motivation to consistently overcome economic and other obstacles to keeping clinic appointments. The lifelong commitment patients understand themselves to be making in initiating ART, a sense of caring and expectation of success from providers, and solidarity with fellow patients all contribute. The data point to patients' subjective sense of connectedness to care as a significant, and to date underappreciated, antecedent of retention (see Figure 1). 10.1371/journal.pmed.1001369.g001 Figure 1 How missed visits may become disengagement from HIV/AIDS treatment and care in Africa. Discussion This qualitative study reveals the importance of recognizing the unintentional origins of many missed visits, the often hidden complexity of reasons for missing, and the ways in which reasons change over time. A prospective approach to the qualitative data revealed both the transitory nature of some obstacles to clinic attendance and a trajectory whereby initial obstacles develop into reluctance to return. In highlighting these broader dimensions and identifying “reluctance to return” as an analytic construct, our aim is to move away from a narrow focus on individual barriers toward a larger and more integrated explanation. The prominence of reluctance to return in interviewee accounts of absences from care signals a potential caution for providers overseeing initiation of ART. Patient education in clinical settings for ART initiation in Africa has featured stern warnings about the lifelong commitment treatment represents, the meaning and importance of medication adherence, and the dire consequences of lapses. Patients' feelings of shame at missing visits and fear of clinic staff's negative response to absences may indicate just how seriously they have taken these warnings. Educational efforts intended to maximize the benefits of ART for patients may paradoxically be driving some away from care. How shall we understand the patient complaints of harsh treatment by staff seen in accounts of reluctance to return? The quality of relationships between patients and health care providers in poor countries has received relatively little research attention. However, the available literature does clearly indicate that friction between the two groups, and reports of “abuse” by clinical staff, are neither specific to HIV/AIDS care nor limited to the sites and countries represented here [47]–[53]. Analyses shedding light on the origins of friction are scarce, but suggest as contributing factors the overwhelming numbers of patients and the emotional strain of HIV/AIDS care provision [54]–[57], perceived threats to professional identity [47],[52], and conflicting priorities of patients and staff [51]. Qualitative research in medicine and public health intentionally aims for in-depth analysis rather than generalizable results. Nevertheless, single site qualitative studies may reflect limitations in resources more than dictates of research design. This study was carried out at three HIV treatment sites in three sub-Saharan African countries. Results reflect commonalities and contrasts across the three patient participant groups. In all three, visits are missed both unintentionally and by design, and evolve into reluctance to return. The specific forms this pattern takes vary, however. The availability of data from three sites in this study offer the advantage of a broader base for analysis, but do not allow for formal cross-site comparison, as the qualitative samples were not designed to be representative. The recent shift in emphasis from increasing access to HIV treatment to enhancing retention in care has led to a number of suggestions and changes aimed at reducing absences. Some of these are structural, e.g., reorganizations of services to make clinic attendance more convenient and efficient (decentralization, reduced waiting times, reduced visit frequency) [58]. Others feature one or another form of community-based support [59],[60]. Returning patients to care following an absence has received less attention as an intervention objective overall. Yet recent research confirms substantial numbers of lost patients are alive and can be located [7],[8],[38],[61],[62]. This study calls attention to reluctance to return as a retention barrier. It follows that interventions designed to address and resolve reluctance might inspire “missing” patients to return to care [61]. To target return to care (rather than prevention of missed visits) would be to bring a harm reduction approach to the retention problem, and to recognize that, while not optimal, absences will be unavoidable over a lifetime of treatment. A harm reduction approach would seek to reduce barriers to re-engagement. The process through which unintentional and intentional missed visits evolve into a weakened sense of connectedness, reluctance to return, and, ultimately, disengagement from care points to an underlying exchange-based relationship between health care providers and HIV/AIDS patients receiving care and ART. In return for access to lifesaving treatment and care, patients are expected to, and agree to, reciprocate with adherence to both medication and clinic appointments. The commitment entails a moral obligation; missed visits are thus a moral failing. Understanding the moral dimensions of the treatment relationship makes sense of patients' shame, justifies “scolding” by providers, and explains the common usage of the term “defaulter” (i.e., someone who fails to repay a debt) to refer to patients who miss clinic appointments in sub-Saharan Africa. This study has a number of limitations. First, the study is based on a convenience sample of patients who could be located through tracking. Reasons for missed visits among persons who could not be located are not represented. Social desirability bias and recall bias may have also resulted in some reasons for missing visits not appearing in the data. Neither reasons for returning to care following an absence nor differences across the clinical sites is examined. A limitation of this analysis qualitatively is that it reflects only a single perspective: the patient's perspective. In a more comprehensive qualitative examination, multiple perspectives on the retention problem would be represented. Conclusion International scale-up of treatment and care for HIV/AIDS has been a resounding public health success. To realize full benefit from the initiative, high rates of long-term retention are essential. Retention research focusing on Africa has shed considerable light on the dimensions of the problem and on reasons for absences from care as directly reported by patients. This paper offers a broader and more complete explanation of disengagement and a new explanatory construct: reluctance to return. To focus on return is to acknowledge the inevitability of absences over a lifetime course of treatment for HIV/AIDS. Efforts to prevent missed clinic visits complemented by moves to minimize barriers to re-entry into care are more likely than either alone to keep missed visits from turning into long-term disengagement.
                Bookmark

                Author and article information

                Contributors
                Role: ConceptualizationRole: Funding acquisitionRole: InvestigationRole: MethodologyRole: SupervisionRole: Writing – original draftRole: Writing – review & editing
                Role: InvestigationRole: MethodologyRole: Project administrationRole: SupervisionRole: Writing – review & editing
                Role: ConceptualizationRole: Funding acquisitionRole: InvestigationRole: MethodologyRole: SupervisionRole: Writing – original draftRole: Writing – review & editing
                Role: ConceptualizationRole: Formal analysisRole: Funding acquisitionRole: MethodologyRole: SoftwareRole: SupervisionRole: ValidationRole: VisualizationRole: Writing – review & editing
                Role: InvestigationRole: MethodologyRole: Project administrationRole: SupervisionRole: Writing – review & editing
                Role: InvestigationRole: MethodologyRole: Project administrationRole: SupervisionRole: Writing – review & editing
                Role: InvestigationRole: MethodologyRole: Project administrationRole: SupervisionRole: Writing – review & editing
                Role: Formal analysisRole: InvestigationRole: MethodologyRole: SoftwareRole: ValidationRole: VisualizationRole: Writing – review & editing
                Role: ConceptualizationRole: InvestigationRole: MethodologyRole: Project administrationRole: SupervisionRole: Writing – review & editing
                Role: InvestigationRole: MethodologyRole: Project administrationRole: SupervisionRole: Writing – review & editing
                Role: MethodologyRole: Writing – review & editing
                Role: Formal analysisRole: MethodologyRole: SoftwareRole: ValidationRole: VisualizationRole: Writing – review & editing
                Role: Formal analysisRole: MethodologyRole: SoftwareRole: ValidationRole: VisualizationRole: Writing – review & editing
                Role: Formal analysisRole: MethodologyRole: SoftwareRole: ValidationRole: VisualizationRole: Writing – review & editing
                Role: ConceptualizationRole: Funding acquisitionRole: InvestigationRole: MethodologyRole: Project administrationRole: SupervisionRole: Writing – review & editing
                Role: ConceptualizationRole: Funding acquisitionRole: InvestigationRole: MethodologyRole: Project administrationRole: SupervisionRole: Writing – review & editing
                Role: Academic Editor
                Journal
                PLoS Med
                PLoS Med
                plos
                plosmed
                PLoS Medicine
                Public Library of Science (San Francisco, CA USA )
                1549-1277
                1549-1676
                25 July 2017
                July 2017
                : 14
                : 7
                : e1002357
                Affiliations
                [1 ] Haitian Study Group for Kaposi’s Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti
                [2 ] Division of Global Health Equity, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America
                [3 ] AIDS Prevention Program, Florida International University, Miami, Florida, United States of America
                [4 ] Department of Global Health and Social Medicine, Harvard Medical School, Harvard University, Boston, Massachusetts, United States of America
                [5 ] Center for Global Health, Department of Medicine, Weill Cornell Medical College, Cornell University, New York, New York, United States of America
                [6 ] Division of General Internal Medicine, Department of Medicine, Weill Cornell Medical College, Cornell University, New York, New York, United States of America
                [7 ] Analysis Group, Boston, Massachusetts, United States of America
                University of California, San Francisco, UNITED STATES
                Author notes

                The authors have declared that no competing interests exist.

                Author information
                http://orcid.org/0000-0001-7464-275X
                http://orcid.org/0000-0002-9689-5413
                Article
                PMEDICINE-D-17-00266
                10.1371/journal.pmed.1002357
                5526526
                28742880
                92792346-8368-4735-9381-6ece4c2779bd
                © 2017 Koenig et al

                This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 24 January 2017
                : 16 June 2017
                Page count
                Figures: 3, Tables: 3, Pages: 15
                Funding
                Funded by: funder-id http://dx.doi.org/10.13039/100000060, National Institute of Allergy and Infectious Diseases;
                Award ID: R01AI104344
                Award Recipient :
                This project was supported by the National Institute of Allergy and Infectious Diseases, grant number R01AI104344. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                Biology and Life Sciences
                Immunology
                Vaccination and Immunization
                Antiviral Therapy
                Antiretroviral Therapy
                Medicine and Health Sciences
                Immunology
                Vaccination and Immunization
                Antiviral Therapy
                Antiretroviral Therapy
                Medicine and Health Sciences
                Public and Occupational Health
                Preventive Medicine
                Vaccination and Immunization
                Antiviral Therapy
                Antiretroviral Therapy
                Biology and Life Sciences
                Microbiology
                Medical Microbiology
                Microbial Pathogens
                Viral Pathogens
                Immunodeficiency Viruses
                HIV
                Medicine and Health Sciences
                Pathology and Laboratory Medicine
                Pathogens
                Microbial Pathogens
                Viral Pathogens
                Immunodeficiency Viruses
                HIV
                Biology and Life Sciences
                Organisms
                Viruses
                Viral Pathogens
                Immunodeficiency Viruses
                HIV
                Biology and Life Sciences
                Organisms
                Viruses
                Immunodeficiency Viruses
                HIV
                Biology and life sciences
                Organisms
                Viruses
                RNA viruses
                Retroviruses
                Lentivirus
                HIV
                Biology and Life Sciences
                Microbiology
                Medical Microbiology
                Microbial Pathogens
                Viral Pathogens
                Retroviruses
                Lentivirus
                HIV
                Medicine and Health Sciences
                Pathology and Laboratory Medicine
                Pathogens
                Microbial Pathogens
                Viral Pathogens
                Retroviruses
                Lentivirus
                HIV
                Biology and Life Sciences
                Organisms
                Viruses
                Viral Pathogens
                Retroviruses
                Lentivirus
                HIV
                Medicine and health sciences
                Diagnostic medicine
                HIV diagnosis and management
                Biology and Life Sciences
                Microbiology
                Medical Microbiology
                Microbial Pathogens
                Viral Pathogens
                Immunodeficiency Viruses
                HIV
                HIV-1
                Medicine and Health Sciences
                Pathology and Laboratory Medicine
                Pathogens
                Microbial Pathogens
                Viral Pathogens
                Immunodeficiency Viruses
                HIV
                HIV-1
                Biology and Life Sciences
                Organisms
                Viruses
                Viral Pathogens
                Immunodeficiency Viruses
                HIV
                HIV-1
                Biology and Life Sciences
                Organisms
                Viruses
                Immunodeficiency Viruses
                HIV
                HIV-1
                Biology and life sciences
                Organisms
                Viruses
                RNA viruses
                Retroviruses
                Lentivirus
                HIV
                HIV-1
                Biology and Life Sciences
                Microbiology
                Medical Microbiology
                Microbial Pathogens
                Viral Pathogens
                Retroviruses
                Lentivirus
                HIV
                HIV-1
                Medicine and Health Sciences
                Pathology and Laboratory Medicine
                Pathogens
                Microbial Pathogens
                Viral Pathogens
                Retroviruses
                Lentivirus
                HIV
                HIV-1
                Biology and Life Sciences
                Organisms
                Viruses
                Viral Pathogens
                Retroviruses
                Lentivirus
                HIV
                HIV-1
                Medicine and Health Sciences
                Health Care
                Health Care Providers
                Medical Doctors
                Physicians
                People and Places
                Population Groupings
                Professions
                Medical Doctors
                Physicians
                People and places
                Geographical locations
                North America
                Caribbean
                Haiti
                Biology and Life Sciences
                Microbiology
                Virology
                Viral Transmission and Infection
                Viral Load
                Medicine and health sciences
                Diagnostic medicine
                HIV clinical manifestations
                Custom metadata
                We have included the anonymized dataset as a Supporting Information file ( S1 Data).

                Medicine
                Medicine

                Comments

                Comment on this article